Leydig cell tumour
Leydig cell tumour is a rare, usually benign, neoplasm that originates from the Leydig cells in the testis. It is named after the German anatomist Franz von Leydig, who first described these cells in 1850.
Epidemiology
Leydig cell tumours account for 1-3% of all testicular neoplasms. They are most commonly diagnosed in adults aged 30-60, but can occur at any age, including in children.
Pathophysiology
Leydig cells are found within the interstitial tissue of the testis and are responsible for the production of testosterone. In Leydig cell tumours, these cells proliferate abnormally, leading to the formation of a tumour.
Clinical Presentation
Patients with Leydig cell tumours may present with a testicular mass or swelling. Some patients may also have symptoms related to increased testosterone production, such as gynecomastia (enlargement of male breast tissue), accelerated growth in children, or virilization (development of male secondary sexual characteristics) in females.
Diagnosis
The diagnosis of Leydig cell tumour is usually confirmed by histopathology following surgical removal of the tumour. Imaging studies such as ultrasound and magnetic resonance imaging (MRI) can also be used to identify and characterize the tumour.
Treatment
The primary treatment for Leydig cell tumours is surgical removal of the tumour, known as orchiectomy. In some cases, testis-sparing surgery may be possible. The role of chemotherapy and radiotherapy in the treatment of Leydig cell tumours is currently unclear and is the subject of ongoing research.
Prognosis
The prognosis for patients with Leydig cell tumours is generally good, as the majority of these tumours are benign. However, a small proportion of Leydig cell tumours can be malignant and may spread to other parts of the body.
See Also
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
